
TrueLab Grants Bionyra Global Rights to Immunology Assets in $985M Deal
Ningbo-based TrueLab Biopharmaceutical has signed an exclusive licensing agreement with clinical-stage startup Bionyra Pharma, granting the latter worldwide rights—excluding Greater China—to two advanced antibody therapies. The deal, valued at up to $985 million, includes upfront payments, development milestones, and a minority equity stake for TrueLab.
























.jpg)


